•   
  •   
  •   

Technology China Covid-19 vaccine: Inside the company at the forefront of China's push to develop a coronavirus vaccine

13:30  10 october  2020
13:30  10 october  2020 Source:   cnn.com

Experts worry that a COVID-19 vaccine won't help if not enough people are willing to get one

  Experts worry that a COVID-19 vaccine won't help if not enough people are willing to get one Advocates hope to convince an often reluctant public that getting a COVID-19 vaccine when there is one will be essential to beat the virus.Israel, United Arab Emirates reach historic deal

CoronaVac, the vaccine candidate from Sinovac, is part of China ' s push to be at the forefront of rolling out immunizations against the deadly novel coronavirus -- and to demonstrate its scientific prowess. CoronaVac, a Covid - 19 vaccine candidate produced by Sinovac Biotech, is one of the

Not everyone in China will need to get vaccinated against Covid - 19 , according to the country's top medical official, as Beijing looks to prioritize frontline Inside the company at the forefront of China ' s push to develop a coronavirus vaccine . Any potential vaccine would instead be prioritized

Inside the white, sterile walls of a new building on the southern outskirts of Beijing, two employees donning masks and rubber gloves are busy pipetting a clear, colorless liquid into rows of small vials.

a close up of a hand: In this picture taken on April 29, 2020, an engineer shows an experimental vaccine for the COVID-19 coronavirus that was tested at the Quality Control Laboratory at the Sinovac Biotech facilities in Beijing. - Sinovac Biotech, which is conducting one of the four clinical trials that have been authorised in China, has claimed great progress in its research and promising results among monkeys. (Photo by NICOLAS ASFOURI / AFP) / TO GO WITH Health-virus-China-vaccine,FOCUS by Patrick Baert (Photo by NICOLAS ASFOURI/AFP via Getty Images) © NICOLAS ASFOURI/AFP/AFP via Getty Images In this picture taken on April 29, 2020, an engineer shows an experimental vaccine for the COVID-19 coronavirus that was tested at the Quality Control Laboratory at the Sinovac Biotech facilities in Beijing. - Sinovac Biotech, which is conducting one of the four clinical trials that have been authorised in China, has claimed great progress in its research and promising results among monkeys. (Photo by NICOLAS ASFOURI / AFP) / TO GO WITH Health-virus-China-vaccine,FOCUS by Patrick Baert (Photo by NICOLAS ASFOURI/AFP via Getty Images)

In some areas, the interior fit-out is still underway. Outside, construction vehicles are digging up dirt.

The Biggest Unanswered Questions About a Covid-19 Vaccine

  The Biggest Unanswered Questions About a Covid-19 Vaccine A vaccine for the coronavirus that causes covid-19 appears to be our best strategy to ending the current pandemic. Unfortunately, the fastest time frame in which scientists have managed to create any vaccine in history was four years, and there’s already plenty of skepticism surrounding the safety, availability, and effectiveness of any future covid-19 inoculation. So let’s go over the most pressing questions. © Photo: Chandan Khanna (Getty Images) A lab technician sorts blood samples for a covid-19 vaccination study at the Research Centers of America in Hollywood, Florida on August 13, 2020.

There are currently over 169 COVID - 19 vaccine candidates under development , with 26 of these in the human trial phase. WHO is working in collaboration When a safe and effective vaccine is found, COVAX (led by WHO , GAVI and CEPI ) will facilitate the equitable access and distribution of these

China is a frontrunner in developing coronavirus vaccines . As of mid-May, it had five candidates in The vaccines are being developed by Chinese companies in partnership with academic For example, efforts by China National Biotec Group and Sinovac to develop a SARS vaccine fizzled

The 215,000 square feet (20,000 square meter) production plant was built in recent months specifically for producing a Covid-19 vaccine developed by Chinese pharmaceutical company Sinovac Biotech.

a close up of a device: CoronaVac, a Covid-19 vaccine candidate produced by Sinovac Biotech, is one of the six vaccines worldwide that have entered Phase 3 clinical trials. © NICOLAS ASFOURI/AFP/AFP via Getty Images CoronaVac, a Covid-19 vaccine candidate produced by Sinovac Biotech, is one of the six vaccines worldwide that have entered Phase 3 clinical trials.

CoronaVac, the vaccine candidate from Sinovac, is part of China's push to be at the forefront of rolling out immunizations against the deadly novel coronavirus -- and to demonstrate its scientific prowess.

Scientists globally are racing to find a way to stop to the virus that has infected more than 23 million people and claimed over 800,000 lives. Six vaccine candidates have started Phase 3 clinical trials -- the last step of testing to prove efficacy and safety before seeking approval from regulators -- and three are Chinese.

Coronavirus dampens celebrations in China's wedding gown city

  Coronavirus dampens celebrations in China's wedding gown city Coronavirus dampens celebrations in China's wedding gown cityBut there are few shoppers in the modern mall, a glitzy showcase of the city's huge wedding gown production industry that usually attracts visitors not only from across China but abroad.

A COVID ‑ 19 vaccine is a biotechnology product intended to provide acquired immunity against coronavirus disease 2019 ( COVID ‑ 19 ).

Progress on a vaccine for Covid - 19 has been rapid compared to other viruses, with human trials starting just 67 days after the outbreak began. When a vaccine became available, wealthier countries bought up the supplies, leaving poorer nations at the back of the line, according to WHO

a group of people standing in a room: Chinese President Xi Jinping learns about the progress on a candidate coronavirus vaccine during his visit to the Academy of Military Medical Sciences in Beijing on March 2, 2020. © Xinhua News Agency/Xinhua News Agency/Xinhua News Agency/Getty Images Chinese President Xi Jinping learns about the progress on a candidate coronavirus vaccine during his visit to the Academy of Military Medical Sciences in Beijing on March 2, 2020.

CoronaVac's last-stage trials are being rolled out in Brazil and Indonesia with about 11,000 volunteers.

"If everything goes well, we hope that we can have some results around the end of the year," said Helen Yang, director of investor relations at Sinovac, from the CoronaVac production plant in the Chinese capital's Daxing district.

The Nasdaq-listed biotech company began developing its vaccine in late January, less than a week after Wuhan -- the original epicenter of China's coronavirus outbreak -- went into a strict lockdown. Construction of the plant started in March, and Yang said the facility will eventually produce 300 million doses of the vaccine a year, if it is approved by China's National Medical Products Administration.

Many parents are hesitant to give their kids a Covid-19 vaccine. What if schools require it?

  Many parents are hesitant to give their kids a Covid-19 vaccine. What if schools require it? "This is going to be a huge issue, and I don't think most people understand that yet," a school law attorney said."There is no way in hell I would be playing politics with my daughter's health and safety," said Vargas, 36, an online fitness instructor. If the public school Madison attends and loves says the vaccine is mandatory, "we would find other options," she said.

See also: COVID - 19 vaccine § Clinical trials started in 2020. In a Phase II clinical trial completed in July 2020, CoronaVac showed immunogenicity at a low 3μg dose, providing 92.4 ^ a b Culver D, Gan N. " Inside the company at the forefront of China ' s push to develop a coronavirus vaccine ". CNN.

The Chinese government has approved the use of an experimental Covid - 19 vaccine for the country' s military -- the latest step in a global race to stop the deadly disease caused by the novel coronavirus .

CoronaVac uses an old-fashioned approach -- employing an inactivated whole virus to prompt the body to develop immunity. The virus is grown under controlled conditions and killed chemically, so it cannot replicate to cause disease when injected into the body. This method has long been proven effective with other viruses, and is still used in polio and flu shots, as well as the rabies vaccine.

a man standing in a room: Engineers work on monkey kidney cells for an experimental Covid-19 vaccine at the Sinovac Biotech facilities in Beijing on April 29. © NICOLAS ASFOURI/AFP/AFP via Getty Images Engineers work on monkey kidney cells for an experimental Covid-19 vaccine at the Sinovac Biotech facilities in Beijing on April 29.

A Sinovac spokesperson said the company chose an inactivated vaccine because it was most familiar with this approach.

The US is pushing ahead with a newer type of vaccine made using genetic material from the virus. This type of vaccine is faster to produce, because whole samples of a virus do not have to be cultured, but there is less known about which genetic material to choose from the virus to replicate to induce an strong immune response.

To fast-track the preclinical process -- where researchers develop the vaccine candidate and test it on animals -- Yang said the company had conducted several studies in parallel so it could select the best results.

NFL reportedly discussing playoff bubble following coronavirus cases

  NFL reportedly discussing playoff bubble following coronavirus cases The NFL has already postponed one game and had players test positive for the coronavirus on multiple teams, which has led to talk of potentially needing a bubble plan going forward. That is still on the table, at least for the postseason. © Jasen Vinlove-USA TODAY Sports Discussions about playing games in a postseason bubble have picked up for the NFL internally, according to Jason La Canfora of CBS Sports. The most viable plan would involve the two conference championship games being played in a bubble.

A company in China , Sinovac Biotech, currently has an inactivated SARS-CoV-2 vaccine in clinical Vaccine development can be costly and success uncertain. As compared to a drug that someone may take Barouch: For Covid - 19 , developers are talking about performing as many steps in parallel as

Developing the vaccine took only 14 days, Logunov said in an interview with online publication Created artificially, the vaccine proteins replicate those of Covid - 19 and trigger “an immune Discharge of volunteers who participated in the COVID - 19 vaccine trials at the Main military clinical

Sinovac has also been working closely with China's equivalent of the Food and Drug Administration to speed up the approval process. "Once we complete a certain study, we submit the data ... immediately so they can start to review," Yang added.

In May, Sinovac published in the journal Science the results of animal trials, which found that its vaccine induced effective antibodies in mice and rats, as well as primates such as the rhesus macaques. A month later, the company said its Phase 2 trial of 600 volunteers found the vaccine caused the human body to produce antibodies 14 days after vaccination.

a person wearing sunglasses: A volunteer receives a COVID-19 vaccine produced by Chinese company Sinovac Biotech at the Sao Lucas Hospital, in Porto Alegre, southern Brazil on August 08, 2020. © SILVIO AVILA/AFP/AFP via Getty Images A volunteer receives a COVID-19 vaccine produced by Chinese company Sinovac Biotech at the Sao Lucas Hospital, in Porto Alegre, southern Brazil on August 08, 2020.

But the Phrase 3 trial requires large-scale testing of thousands of participants.

By June, China had largely contained the coronavirus, contending with only small, sporadic outbreaks. China had reported 84,996 Covid-19 cases by Wednesday, with fewer than 2,000 new infections since the start of June -- and more than a third of those were imported, according to the country's National Health Commission (NHC).

Yang said the small number of newly reported Covid-19 cases in China didn't meet the necessary conditions for a Phase 3 trial, so Sinovac reached an agreement with Brazil -- which ranks second in the world for infections, with more than 3.6 million reported cases.

Q&A: How far can Trump go in pushing a COVID-19 vaccine that isn't ready?

  Q&A: How far can Trump go in pushing a COVID-19 vaccine that isn't ready? The Trump administration seems to be going to great lengths to get a COVID-19 vaccine produced by election day. How much can they get away with?President Trump has made clear that his top priority is speed. For a time, his administration rejected the Food & Drug Administration's proposed criteria for assessing vaccine candidates — criteria which make it all but impossible to have a vaccine available by election day.

In collaboration with the Butantan Institute in São Paulo, a Phase 3 study was launched in late July involving 9,000 volunteers, all health professionals who have worked with Covid-19 patients but haven't been infected with the virus, according to São Paulo officials.

In exchange, Brazil was promised 120 million doses of the vaccine, if the tests found it to be effective.

The tests are ongoing, but Dimas Covas, president of the Butantan Institute, said Wednesday preliminary data shows CoronaVac induced immunity in 97% of the people vaccinated after two doses -- a level he said was "fundamental to break the chain of transmission of the coronavirus."

Covas said earlier this month that data on the efficacy of the vaccine could be available by October -- potentially starting the formal approval process in a matter of months. He expects the vaccine to be available to the Brazilian public by January.

"I am very optimistic. I think it would be a reasonable time frame given the performance so far," he said at a public hearing at the Brazilian Chamber of Deputies.

This month, Sinovac also rolled out another Phase 3 trial in Indonesia with 1,620 volunteers. Indonesia's state-owned Bio Farma said in a statement Friday that it signed a preliminary agreement with Sinovac for the bulk purchase of 50 million vaccines from November to March 2021, with guaranteed priority access until the end of next year.

A race for vaccine

With the global race for vaccines heating up, Yang down played competition between biotech companies -- saying demand was too huge for a single company to meet.

Protecting the profits of a few could prevent vaccine access for all

  Protecting the profits of a few could prevent vaccine access for all India and South Africa have put forward a novel proposal to replace our current competition-driven approach with cooperation. At a meeting on Oct. 15, they will be asking the World Trade Organization (WTO) to temporarily relax its rules to allow for more international collaboration in the manufacture of the vaccines and medicines - even without authorization from the companies that created them. Theirs is an ambitious gambit, but one that deserves support. require(["medianetNativeAdOnArticle"], function (medianetNativeAdOnArticle) { medianetNativeAdOnArticle.

The real competition, she said, is with the virus.

"Our speed should be faster than the transmission of the virus instead of competing with others. We like everyone to be successful then there will be enough supply to protect people," Yang said.

The two other Chinese vaccines to have started Phase 3 trials are being developed by the state-owned Sinopharm, while a vaccine from the United Kingdom, produced by the University of Oxford and AstraZeneca has reached this stage, along with two from the United States, one by pharmaceutical giant Pfizer in collaboration with German company BioNTech, and the other by Moderna.

As it stands, 13 companies in China are working on coronavirus vaccines. Of those, nine vaccine candidates are in human trials -- more than in any other country.

Ivan Hung, an infectious diseases specialist at the Hong Kong University School of Medicine, said vaccination is key for countries like China where strict measures have helped keep the percentage of infected people in the population low.

"The overall immunity is very low. And so in these places, definitely the way forward is vaccinations," he said.

Geopolitical implications

Senior US national security officials have warned of alleged Chinese government attempts to steal coronavirus research from American institutions for months. In July, US prosecutors charged two Chinese nationals accused of trying to steal Covid-19 vaccine research on behalf of the government.

China's leader Xi Jinping has repeatedly urged Chinese scientists to accelerate the research and development of coronavirus vaccines. Xiao Yaqing, the country's former top market regulator, told pharmaceutical companies last month to treat coronavirus vaccine development as an "important political task."

Xiao has since been appointed the minister of industry and information technology.

Vaccine storage demands could leave 3B people in virus cold

  Vaccine storage demands could leave 3B people in virus cold GAMPELA, Burkina Faso (AP) — From factory to syringe, the world’s most promising coronavirus vaccine candidates need nonstop sterile refrigeration to work. But despite great strides in equipping developing countries to maintain the vaccine “cold chain,” nearly 3 billion of the world's 7.8 billion people live in places with insufficient temperature-controlled storage for an immunization campaign to bring COVID-19 under control. The result: PoorBut despite great strides in equipping developing countries to maintain the vaccine “cold chain,” nearly 3 billion of the world's 7.8 billion people live in places with insufficient temperature-controlled storage for an immunization campaign to bring COVID-19 under control.

Not only would a safe and effective coronavirus vaccine save lives, deliver scientific prestige and represent a tantalizing opportunity for economic recovery, it could also have significant geopolitical implications.

The Chinese government has faced sharp criticism -- most notably from the US -- for its initial handling of the coronavirus outbreak. Its subsequent "mask diplomacy" -- an effort to ship medical supplies to countries grappling with Covid-19 -- has fueled suspicion that it is trying to change the coronavirus narrative.

Winning the vaccine race would present China with an opportunity to shore up its global standing by positioning itself as a leader in fighting the pandemic.

Last month, Philippine President Rodrigo Duterte said he had asked Xi to help the Southeast Asian nation get priority access to a Chinese vaccine.

The number of countries granted such access is growing fast. Besides Brazil and Indonesia, which have been approved for early access from Sinovac, Pakistan -- one of China's closest allies -- will receive early vaccine doses from Sinopharm, if its Phase 3 trials are successful.

In a video summit with African leaders in June, Xi pledged that "once the development and deployment of Covid-19 vaccine is completed in China, African countries will be among the first to benefit."

This month, China's ambassador in Afghanistan, Wang Yu, told the Afghanistan Times that "once China's vaccine is successfully developed and produced, it will be our priority to consider providing the vaccine to Afghan people."

And on Monday, Chinese Premier Li Keqiang said Beijing would also give priority access to Cambodia, Myanmar, Laos, Thailand and Vietnam.

"Emergency use"

Within China, authorities have rolled out coronavirus vaccines for "emergency use" before the last-stage trials are finished.

Last weekend, a senior official from the NHC revealed that China has been using an experimental vaccine on people who work in high-risk professions since July, including front line medical professionals and border inspectors.

The vaccine, developed by Sinopharm, is still in Phase 3 trials in the United Arab Emirates, Peru, Morocco and Argentina.

Zheng Zhongwei, director of the Science and Technology Development Center of the NHC, told China's state broadcaster that the "emergency use" of a vaccine during a "major public health incident" was in accordance with the country's vaccine law.

It comes after the Chinese government approved the use of a different vaccine candidate for the country's military in June.

However, on Monday, Dr. Anthony Fauci -- the top US infectious disease expert -- warned against early emergency use authorization, explaining that such a step could damage efforts to develop other vaccines.

"One of the potential dangers if you prematurely let a vaccine out is that it would make it difficult, if not impossible, for the other vaccines to enroll people in their trial," he said.

Vaccine storage demands could leave 3B people in virus cold .
GAMPELA, Burkina Faso (AP) — From factory to syringe, the world’s most promising coronavirus vaccine candidates need nonstop sterile refrigeration to work. But despite great strides in equipping developing countries to maintain the vaccine “cold chain,” nearly 3 billion of the world's 7.8 billion people live in places with insufficient temperature-controlled storage for an immunization campaign to bring COVID-19 under control. The result: PoorBut despite great strides in equipping developing countries to maintain the vaccine “cold chain,” nearly 3 billion of the world's 7.8 billion people live in places with insufficient temperature-controlled storage for an immunization campaign to bring COVID-19 under control.

usr: 3
This is interesting!